Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiency

Journal of Gene Medicine

Volumn 2, Issue 1, 2000, Pages 22-31

  Laufs, Stephanie ^a   Kim, Seon Hee ^b   Kim, Sunyoung ^b   Blau, Nenad ^a   Thöny, Beat ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Seoul National University   (South Korea)

Author keywords

Gene transfer; Hyperphenylalaninemia; Neurotransmitter depletion; Retrovirus; Tetrahydrobiopterin deficiency

Indexed keywords

UNIDENTIFIED RETROVIRUS;

5,6,7,8-TETRAHYDROBIOPTERIN; 6 PYRUVOYLTETRAHYDROPTERIN SYNTHASE; 6-PYRUVOYLTETRAHYDROPTERIN SYNTHASE; BIOPTERIN; CYTOKINE; DRUG DERIVATIVE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LYASE; NEOMYCIN; RECOMBINANT DNA; TETRAHYDROBIOPTERIN;

ARTICLE; BIOSYNTHESIS; CELL LINE; CYTOLOGY; FIBROBLAST; GENE; GENE TRANSFER; GENE VECTOR; GENETIC MARKER; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; RETROVIRUS; RIBOSOME; SKIN;

BIOPTERIN; CELL LINE; CYTOKINES; DNA, RECOMBINANT; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENES; GENETIC MARKERS; GENETIC VECTORS; GTP CYCLOHYDROLASE; HUMANS; NEOMYCIN; PHOSPHORUS-OXYGEN LYASES; RETROVIRIDAE; RIBOSOMES; SKIN; TRANSDUCTION, GENETIC;

EID: 0033649906     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(200001/02)2:1<22::AID-JGM86>3.0.CO;2-1     Document Type: Article

References (66)

1. Kaufman S. New tetrahydrobiopterin-dependent systems. Annu Rev Nutr 1993; 13: 261-286.
2. Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. J Nutr Biochem 1991; 2: 411-423.
3. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. J Biol Chem 1990; 265: 3189-3192.
4. Milstien S, Kaufman S, Sakai N. Tetrahydrobiopterin biosynthesis defects examined in cytokine-stimulated fibroblasts. J Inherit Metab Dis 1993; 16: 975-981.
5. Dassesse D, Hemmens B, Cuvelier L, Resibois A. GTP cyclohydrolase I-like immunoreactivity in rat brain. Brain Res 1997; 777: 187-201.
6. Ichinose H, Ohye T, Takahashi E, Seki N, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8: 236-242.
7. Ichinose H, Ohye T, Matsuda Y, et al. Characterization of mouse and human GTP cyclohydrolase I genes - mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem 1995; 270: 10062-10071.
8. Thöny B, Heizmann CW, Mattei M-G. Chromosomal localization of two human genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tetrahydropterin synthase maps to 11q22.3-q23.3, and pterin-4a-carbinolamine dehydratase maps to 10q22. Genomics 1994; 19: 365-368.
9. Thöny B, Heizmann CW, Mattei M-G. Human GTP-cyclohydrolase I gene and sepiapterin reductase gene map to region 14q21-q22 and 2p14-p12, respectively, by in situ hybridization. Genomics 1995; 26: 168-170.
10. Kluge C, Brecevic L, Heizmann CW, et al. Chromosomal localization, genomic structure and characterization of the human gene and a retropseudogene for 6-pyruvoyl-tetrahydropterin synthase. Eur J Biochem 1996; 240: 477-484.
11. Yoneyama T, Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feed-back regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. J Biol Chem 1998; 273: 20102-20108.
12. Nar H, Huber R, Meining W, et al. Atomic structure of GTP cyclohydrolase I. Structure 1995; 3: 459-466.
13. Nar H, Huber R, Auerbach G, et al. Active site topology and reaction mechanism of GTP cyclohydrolase I. Proc Natl Acad Sci U S A 1995; 92: 12120-12125.
14. Nar H, Huber R, Heizmann CW, et al. Three-dimensional structure of 6-pyruvoyl-tetrahydropterin synthase, an enzyme involved in tetrahydrobiopterin biosynthesis. EMBO J 1994; 13: 1255-1262.
15. Bürgisser D, Thöny B, Redweik U, et al. 6-Pyruvoyl tetrahydropterin synthase: an enzyme with a novel type of active site involving both zinc binding and an intersubunit catalytic motif; site-directed mutagenesis of the proposed active center, characterization of the metal binding site and modelling of substrate binding. J Mol Biol 1995; 253: 358-569.
16. Oppliger T, Thöny B, Nar H, et al. Structural and functional consequences of mutations in 6-pyruvoyl-tetrahydropterin synthase causing hyperphenylalaninemia in humans - phosphorylation is a requirement for in vivo activity. J Biol Chem 1995; 270: 29498-29506.
17. Ploom T, Thöny B, Yim J, et al. Crystallographic and kinetic investigations on the mechanism of 6-pyruvoyl tetrahydropterin synthase. J Mol Biol 1999; 286: 851-860.
18. Auerbach G, Nar H. The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP-cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase. Biol Chem 1997; 378: 185-192.
19. Blau N, Thöny B, Heizmann CW, et al. Tetrahydrobiopterin deficiency: from phenotype to genotype. Pteridines 1993; 4: 1-10.
20. Scriver CR, Kaufman S, Eisensmith RC, Woo SLC. The hyperphenylalaninemias. In The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds). New York: McGraw-Hill, 1995; 1015-1075.
21. Thöny B, Blau N. Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. Hum Mutat 1997; 10: 11-20.
22. Blau N, Dhondt JL, Dianzani I, Thöny B. BIODEF and BIOMDB international databases of tetrahydrobiopterin deficiencies. In Chemistry and Biology of Pteridines and Folates, Pfleiderer W, Rokos H (eds). Blackwell Science: Berlin, 1997; 719-726.
23. Brand MP, Hyland K, Engle T, et al. Neurochemical effects following peripheral administration of tetrahydrobiopterin derivatives to the hph-1 mouse. J Neurochem 1996; 66: 1150-1156.
24. Pardridge WM. CNS drug design based on principles of bloodbrain barrier transport. J Neurochem 1998; 70: 1781-1792.
25. Blau N. Inborn errors of pterin metabolism. Annu Rev Nutr 1988; 8: 185-209.
26. Blau N, Thöny B, Spada M, Ponzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. Turk J Pediatr 1996; 38: 19-35.
27. Blömer U, Naldini L, Verma IM, Trono D, Gage FH. Applications of gene therapy to the CNS. Hum Mol Genet 1996; 5: 1397-1404.
28. Kang UJ. Potential of gene therapy for Parkinson's Disease: neurobiologic issues and new developments in gene transfer methodologies. Move Dis 1998; 13, suppl. 1: 59-72.
29. Thöny B, Leimbacher W, Stuhlmann H, et al. Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. Hum Gene Ther 1996; 7: 1587-1593.
30. Laufs S, Blau N, Thöny B. Retrovirus-mediated double transduction of the GTPCH and PTPS genes allows 6-pyruvoyl-tetrahydropterin synthase-deficient human fibroblasts to synthesize and release tetrahydrobiopterin. J Neurochem 1998; 71: 33-40.
31. Morgan R, Couture L, Elroy-Stein O, et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycystronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
32. Thöny B, Leimbacher W, Blau N, et al. Hyperphenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecular characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. Am J Hum Genet 1994; 54: 782-792.
33. DuBridge RB, Tang P, Hsia HC, et al. Analysis of mutations in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379-387.
34. Ausubel FM, Brent R, Kingston RE, et al. (eds). Current Protocols in Molecular Biology. New York: John Wiley & Sons, 1992.
35. Togari A, Ichinose H, Matsumoto S, et al. Multiple mRNA forms of human GTP cyclohydrolase I. Biochem Biophys Res Commun 1992; 187: 359-365.
36. Gütlich M, Jaeger E, Rucknagel K, et al. Human GTP cyclohydrolase I: only one out of three cDNA isoforms gives rise to the active enzyme. Biochem J 1994; 302: 215-221.
37. Thöny B, Leimbacher W, Bürgisser D, Heizmann CW. Human 6-pyruvoyl-tetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. Biochem Biophys Res Commun 1992; 189: 1437-1443.
38. Soneoka Y, Cannon PM, Ramsdale EE, et of. A transient three-plasmid epxression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
39. Kotani H, Newton PB, Zhang S, et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
40. Curtius H-C, Blau N, Kuster T. Pterins. In Techniques in Diagnostic Human Biochemical Genetics, Hommes FA (ed). New York: Wiley-Liss, 1991; 377-396.
41. Fukushima T, Nixon JC. Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 1980; 102: 176-188.
42. Kim SH, Yu SS, Park JS, et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994-1004.
43. Snyder EY, Fisher LJ. Gene therapy in neurology. Curr Opin Pediatr 1996; 8: 558-568.
44. Dirks W, Wirth M, Hauser H. Dicistronic transcription units for gene expression in mammalian cells. Gene 1993; 128: 247-249.
45. Sugimoto Y, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechniques 1994; 12: 694-698.
46. Mountford PS, Smith AG. Internal ribosome entry sites and dicistronic RNAs in mammalian transgenes. Trends Genet 1995; 11: 179-184.
47. Dranoff G, Jaffee EM, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GMCSF stimulates potent, specific and long lasting antitumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539-3543.
48. Zitvogel L, Tahara H, Cai Q. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 1994; 5: 1493-1506.
49. Mouiller P, Marechal V, Danos O, Heard JM. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts. Transplantation 1993; 56: 427-432.
50. Laufs S, Leimbacher W, Kim S, et al. Alternative, gene therapeutic approaches to treatment of tetrahydrobiopterin deficiency by gene transfer: generation of retroviral vectors. In Chemistry and Biology of Pteridines and Folates, Pfleiderer W, Rokos H (eds). Blackwell Science, 1997; 737-740.
51. Bräutigam M, Dreesen R, Herken H. Tetrahydrobiopterin and total biopterin content of neuroblastoma (N1E-115, N2A) and pheochromocytoma (PC-12) clones and the dependence of catecholamine synthesis on tetrahydrobiopterin concentration in PC-12 cells. J Neurochem 1984; 42: 390-396.
52. Anastasiadis PZ, States JC, Imernan BA, et al. Mitogenic effects of tetrahydrobiopterin in PC12 cells. Mol Pharmacol 1996; 49: 149-155.
53. 14C-tetrahydrobiopterin and its developmental change in mice. J Pharmacol Exp Ther 1993; 267: 971-978.
54. Anastasiadis PZ, Kuhn DM, Levine RA. Tetrahydrobiopterin uptake in rat brain synaptosomes, cultured PC12 cells, and rat striatum. Brain Res 1994; 665: 77-84.
55. Tsutsui M, Milstien S, Katusic ZS. Effect of tetrahydrobiopterin on endothelial function in canine middle cerebral arteries. Circ Res 1996; 79: 336-342.
56. Kinsoshita H, Katusic ZS. Exogenous tetrahydrobiopterin causes endothelium-dependent contractions in isolated canine basilar artery. Am J Physiol 1996; 40: H738-H743.
57. Tzeng E, Yoneyama T, Hatakeyama K, et al. Vascular inducible nitric oxide synthase gene therapy: requirement for guanosine triphosphate cyclohydrolase I. Surgery 1996; 120: 315-321.
58. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15.
59. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-46.
60. Rosenblum WI. Tetrahydrobiopterin, a cofactor for nitric oxide synthase, produces endothelium-dependent dilation of the mouse pial arterioles. Stroke 1997; 28: 186-189.
61. Harding CO, Wild K, Chang D, et al. Metabolic engineering as therapy for inborn errors of metabolism - development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther 1998; 5: 677-783.
62. Naldini L, Blömer U, Gage FH, et al. Efficient transfer, integration and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11387.
63. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 1996; 272: 263-267.
64. Fisher LJ, Jinnah HA, Kale LC, et al. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-DOPA. Neuron 1991; 6: 371-380.
65. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci 1993; 13: 5203-5211.
66. McBurney MW, Staines WA, Boekelheide K, Parry D, Jardine K, Pickavance J. Murine PGK-1 promoter drives widespread but not uniform expression in transgenic mice. Dev Dyn 1994; 200: 278-293.